• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Choosing the optimal antihypertensive dose regimen.

作者信息

Hansson L

机构信息

Department of Geriatrics, University of Uppsala, Sweden.

出版信息

J Hypertens Suppl. 1995 Dec;13(4):S1-4. doi: 10.1097/00004872-199512002-00001.

DOI:10.1097/00004872-199512002-00001
PMID:8824680
Abstract

THE OPTIMAL DOSE-RESPONSE CURVE: From a pharmacological point of view the optimal dose regimen of an antihypertensive agent is relatively easy to define. By constructing dose-response curves the most effective dose can usually be identified. From a clinical point of view the problem is more complicated. FACTORS THAT INFLUENCE THE IDEAL CLINICAL DOSE: The most important consideration is the relationship between efficacy and adverse effects. Ideally, dose-response curves for both antihypertensive efficacy and adverse effects should be produced. From these curves the optimal dose may be established. Drugs such as lacidipine that demonstrate a good overlap between efficacy and tolerability provide a wide therapeutic window. PRACTICAL CONSIDERATIONS: It may be less effective to increase the dose of a single drug until the desired effect is obtained; the addition of another therapeutic agent is often preferable. Cost is also a factor. If the dose-response curve flattens, it may not be cost-effective to recommend a higher dose, even if the higher dose is slightly more effective. Furthermore, if an unnecessarily high dose has been recommended, doctors will soon learn to prescribe half the dose or less, which may have budgetary implications for the manufacturer. The choice of the optimal dose regimen is a complicated, multifactorial problem. The aim is to find a reasonable balance between efficacy and adverse effects, at a competitive cost.

摘要

相似文献

1
Choosing the optimal antihypertensive dose regimen.
J Hypertens Suppl. 1995 Dec;13(4):S1-4. doi: 10.1097/00004872-199512002-00001.
2
Practical relevance of the 24-hour trough: peak ratio of antihypertensive drugs.抗高血压药物24小时谷值:峰值比的实际意义。
J Hypertens Suppl. 1995 Aug;13(2):S109-12. doi: 10.1097/00004872-199508001-00018.
3
Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats.固定剂量复方制剂治疗高血压的理论依据:循环往复。
Drugs. 2002;62(3):443-62. doi: 10.2165/00003495-200262030-00003.
4
Adverse reactions to antihypertensive therapy.抗高血压治疗的不良反应。
Cardiovasc Drugs Ther. 1998 May;12(2):189-96. doi: 10.1023/a:1007735311894.
5
Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control?
Clin Ther. 2004;26 Suppl A:A21-7. doi: 10.1016/s0149-2918(04)90142-7.
6
Low-dose antihypertensive combination therapy: its rationale and role in cardiovascular risk management.小剂量降压联合治疗:其原理及在心血管风险管理中的作用。
Am J Hypertens. 1999 Aug;12(8 Pt 2):73S-79S. doi: 10.1016/s0895-7061(99)00112-0.
7
[Fixed-dose combinations in the first line of antihypertensive therapy].[抗高血压治疗一线固定剂量复方制剂]
Acta Pharm Hung. 2007;77(3):180-4.
8
Clinical overview of irbesartan: expanding the therapeutic window in hypertension.厄贝沙坦临床概述:拓展高血压治疗窗口
J Hypertens Suppl. 1997 Dec;15(7):S27-33.
9
[Atenolol/nifedipine combination: efficacy and tolerability of low dose synergistic bitherapy in the treatment of arterial hypertension].阿替洛尔/硝苯地平联合用药:低剂量协同双药疗法治疗动脉高血压的疗效及耐受性
Drugs. 1998;56 Suppl 2:31-43. doi: 10.2165/00003495-199856002-00004.
10
Healthcare benefits of very-low-dose combination treatment used in the management of hypertension.
J Hypertens Suppl. 2001 Nov;19(4):S29-36.